Neurocrine Biosciences director sells 1,250 shares
Neurocrine Biosciences director Leslie V. Norwalk reported trades in company stock.
Rhea-AI Filing Summary
Neurocrine Biosciences director Leslie V. Norwalk reported trades in company stock. On July 28, 2026, she sold 1,250 common shares at a weighted-average price of $182.006 per share in multiple open-market transactions executed pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025, with issuer policy restricting later plan modifications. On July 29, 2026, she exercised Non-Qualified Stock Options to acquire 842 common shares at an exercise price of $139.43 per share, leaving 2,140 options from that grant outstanding, which expire on May 22, 2034.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Norwalk Leslie V
Role
Director
Sold
1,250 shs ($228K)
Approx. gross sale proceeds
$228K
Approx. exercise cost
$117K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option F3 | 842 | $0.00 | $0.00 |
| Exercise | Common Stock | 842 | $139.43 | $117K |
| Sale | Common Stock F1, F2 | 1,250 | $182.006 | $228K |
Holdings After Transaction:
Non-Qualified Stock Option — 2,140 contracts (Direct);
Common Stock — 2,430 shares (Direct)
Footnotes (3)
- F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Option vested in 12 monthly installments beginning June 22, 2024.
Key Figures
Common shares sold: 1,250 shares
Sale price (weighted average): $182.006 per share
Options exercised: 842 shares
+3 more
6 metrics
Common shares sold
1,250 shares
Open-market sale on July 28, 2026 by director Leslie V. Norwalk
Sale price (weighted average)
$182.006 per share
Weighted-average sales price; individual trades ranged from $182.00 to $182.03
Options exercised
842 shares
Non-Qualified Stock Options exercised for common stock on July 29, 2026
Option exercise price
$139.43 per share
Exercise price of Non-Qualified Stock Options converted into common shares
Options remaining after exercise
2,140 options
Non-Qualified Stock Options held directly following the July 29, 2026 exercise
Option expiration date
May 22, 2034
Expiration date of the Non-Qualified Stock Option grant involved in the exercise
Key Terms
Rule 10b5-1 trading plan, Non-Qualified Stock Option, weighted average sales price per share, derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"executed by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"security_title: Non-Qualified Stock Option with an exercise price of $139.43 per share"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
derivative security financial
"transaction_code M described as Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Neurocrine Biosciences (NBIX) director Leslie V. Norwalk report?
Leslie V. Norwalk reported a sale of 1,250 common shares on July 28, 2026 and an exercise of 842 stock options on July 29, 2026, receiving common shares at a lower exercise price than the contemporaneous market sale price.
What stock options did Leslie V. Norwalk exercise in Neurocrine Biosciences (NBIX)?
She exercised 842 Non-Qualified Stock Options for NBIX common stock on July 29, 2026 at an exercise price of $139.43 per share. The option grant vests in 12 monthly installments beginning June 22, 2024 and expires on May 22, 2034.
How many Neurocrine Biosciences (NBIX) options does Leslie V. Norwalk still hold from this grant?
After exercising 842 options, she continues to hold 2,140 Non-Qualified Stock Options from the same grant. These options relate to NBIX common stock and are scheduled to expire on May 22, 2034, based on the reported position data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
